COMMUNIQUÉS West-GlobeNewswire

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
13/05/2026
Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of [...]
ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026
13/05/2026
In first line, iadademstat with azacitidine and venetoclax continues to show favorable safety and 100% ORR, with a composite complete remission rate (CRc) of 93% (with 79% CR), and an estimated 12-month OS of 74% In [...]
Candel Therapeutics to Present at Upcoming Investor Conferences
13/05/2026
NEEDHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve [...]
Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center
13/05/2026
Silexion advances toward Phase 2/3 trial in KRAS-driven pancreatic cancer, as SIL204 begins GMP clinical manufacturing in collaboration with global leading manufacturing partner Catalent at its European center of [...]
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
13/05/2026
Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of telitacicept in primary [...]
Lite Strategy Reports Fiscal 2026 Third Quarter Results
13/05/2026
Lite Strategy Continues to Deliver Recurring Yield on Litecoin Holdings and Advance Share Repurchase Program SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Strategy” or the “ [...]
Dyne Therapeutics to Participate in Upcoming Investor Conferences
13/05/2026
WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular [...]
Pyxis Oncology to Participate in Upcoming Investor Conferences
13/05/2026
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will [...]
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
13/05/2026
WEST CHESTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases [...]
CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research
13/05/2026
AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : Among the most guarded structures in human biology, the brain is also one of the hardest to treat. The blood-brain barrier (BBB), a [...]
BrainsWay Reports First Quarter 2026 Financial Results and Operational Highlights
13/05/2026
R evenue grew approximately 35 % y ear- o ver- y ear to $1 5 .5 million for Q1 2026 Net income increased by over 100 % year-over-year to $ 2. 3 million for Q1 2026 Adjusted EBITDA for Q1 of 2026 more than doubled year- [...]
Century Therapeutics Reports First Quarter Financial Results and Business Updates
13/05/2026
CNTY-813, Century’s type 1 diabetes iPSC-derived islet therapy with functional-cure potential, remains on track for IND in 4Q 2026; initial clinical data expected in 2H 2027 Upcoming oral presentation at the American [...]
ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President
13/05/2026
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering patients and their caregivers to better protect against severe allergic reactions [...]
Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update
13/05/2026
- Three patients treated with ZEVASKYN ® in Q1 2026 - - QTC network expands to six sites, with two new additions on the East Coast - - In-licensed radically novel engineered T-cell technology with game changing [...]
InnoCare Announce First Subject Dosed in Phase 1 Clinical Trial of ICP-054, a Novel Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
13/05/2026
- Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ICP-054 (ZB021) in healthy volunteers - Phase 1 SAD and MAD data expected by year-end 2026 BEIJING, May 13, 2026 (GLOBE [...]
Valitor to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
13/05/2026
BERKELEY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced that chief executive officer Gregory D. Kunst will share a [...]
Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
13/05/2026
WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF [...]
Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus
13/05/2026
First-in-human study evaluates weekly IV Sapu003 in advanced mTOR-sensitive solid tumors, including HR+/HER2- breast cancer, RCC, NETs, TSC-associated tumors, and HCC SAN DIEGO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- [...]
Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year
13/05/2026
Razor-razorblade business model accelerates, with Q3 cartridge revenue up 59% year-over-year, representing 66% of quarterly sales Nine-month revenue reaches $3.07 million, up 39% year-over-year, building on record first [...]

Pages